BSBrian Stwalley

Brian Stwalley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian Stwalley has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    A table showing the definitions used for each US geographic region

  • Open Access

    Supplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    A schematic diagram of patient disposition and exclusion criteria

  • Open Access

    Supplementary Figure 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

  • Open Access

    Data from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.

  • Open Access

    Supplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    A table showing baseline demographics and disease characteristics divided by SES index

  • Open Access

    Supplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    Additional detail on the methodology for subgroup analyses and statistical analyses

  • Open Access

    Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer

    by Gregory A. Vidal, Julie Katz, Natalia Sadetsky, Elizabeth C. Dabrowski, Peter A. Kaufman, Wendy Verret, Brian Stwalley, Kevin Kalinsky

    Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.


  • Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab.

    by Gurjyot K. Doshi, Nicholas J. Robert, Liwei Chen, Philip K Chan, Viviana Del Tejo, Brian Stwalley, Stephen Huo, Daniel M. Geynisman

    305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), and the treatment paradigm has changed dramatically over the past few years. This real-world study examined treatment patterns and sequences, treatment response, safety, and survival outcomes with this novel first-line (1L) combination therapy among patients diagnosed with metastatic RCC (mRCC) in a community oncology practice setting. Methods: A retrospective analysis of the US Oncology Network’s iKnowMed medical data examined adult patients with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognosis of intermediate- or poor-risk clear cell mRCC who received 1L NIVO+IPI between April 1, 2018, and March 31, 2020. Baseline demographic and clinical characteristics, treatment patterns, and treatment sequence were examined descriptively. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), time to treatment discontinuation (TTD), and time to treatment response (TTR) were analyzed using the Kaplan–Meier method. Treatment-related adverse events (TRAEs) and healthcare resource utilization were also analyzed. Results: A total of 193 adults with stage IV mRCC treated with 1L NIVO+IPI were identified. Median age (range) was 63 (30.0–89.0) years, 73.1% were male, 69.4% were white, 56.7% were IMDC intermediate risk, and 60.6% had a documented Eastern Cooperative Oncology Group performance status of 0 or 1. Median follow-up time (range) was 9.7 (0.1–24.7) months. Median PFS (95% CI) was 17.1 (12.6–21.2) months, and the 1-year landmark PFS rate was 58.3% (50.4–65.4). At 12 months, the OS rate (95% CI) was 75.4% (67.8–81.4). The ORR (95% CI) was 43.2% (34.6–52.1) among patients with a response assessment; the median TTR (range) was 2.8 (0.3–4.1) months and median DoR was not reached. Median TTD (95% CI) was 5.8 (4.5–7.5) months. Among the 63 (31.3%) patients who received second-line therapy, 50.8% received cabozantinib and 12.7% received pazopanib. TRAEs were reported in 47.2% of patients—the most frequently reported were fatigue (13.5%), rash (10.4%), diarrhea (6.7%), nausea (6.2%), colitis (3.6%), and pruritus (3.6%). The treatment-related hospitalization rate was 5.5% and the emergency department visit rate was 3.1%. Conclusions: This real-world study supports the clinical efficacy of 1L NIVO+IPI for patients with mRCC. Our findings also suggest that the NIVO+IPI combination was generally well tolerated in the real-world setting, with low rates of adverse events and healthcare resource utilization.